NetApp, Inc. (NTAP)
NASDAQ: NTAP · Real-Time Price · USD
109.40
+1.61 (1.50%)
At close: Aug 13, 2025, 4:00 PM
109.74
+0.34 (0.32%)
After-hours: Aug 13, 2025, 7:57 PM EDT
CTI BioPharma Stock Forecast
Stock Price Forecast
The 15 analysts that cover CTI BioPharma stock have a consensus rating of "Buy" and an average price target of $122.6, which forecasts a 12.07% increase in the stock price over the next year. The lowest target is $100 and the highest is $160.
Price Target: $122.6 (+12.07%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for CTI BioPharma stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 3 | 3 |
| Buy | 1 | 2 | 2 | 2 | 2 | 2 |
| Hold | 12 | 11 | 11 | 11 | 11 | 11 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 17 | 17 | 17 | 17 | 16 | 16 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citigroup | Citigroup | Hold Maintains $110 → $115 | Hold | Maintains | $110 → $115 | +5.12% | Aug 11, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $115 → $130 | Buy | Maintains | $115 → $130 | +18.84% | Jul 17, 2025 |
| Citigroup | Citigroup | Hold Maintains $105 → $110 | Hold | Maintains | $105 → $110 | +0.55% | Jun 2, 2025 |
| Barclays | Barclays | Buy Maintains $115 → $117 | Buy | Maintains | $115 → $117 | +6.95% | May 30, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $120 → $115 | Buy | Maintains | $120 → $115 | +5.12% | May 30, 2025 |
Financial Forecast
Revenue This Year
6.89B
from 6.57B
Increased by 4.81%
Revenue Next Year
7.24B
from 6.89B
Increased by 5.10%
EPS This Year
7.88
from 5.67
Increased by 39.06%
EPS Next Year
8.65
from 7.88
Increased by 9.75%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 7.1B | 7.6B | 7.9B |
| Avg | 6.9B | 7.2B | 7.6B |
| Low | 6.6B | 6.8B | 7.2B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 8.7% | 9.8% | 9.7% |
| Avg | 4.8% | 5.1% | 5.2% |
| Low | -0.1% | -0.9% | 0.1% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 8.20 | 9.42 | 10.32 |
| Avg | 7.88 | 8.65 | 9.29 |
| Low | 7.45 | 7.69 | 8.26 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 44.6% | 19.4% | 19.3% |
| Avg | 39.1% | 9.7% | 7.4% |
| Low | 31.4% | -2.4% | -4.5% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.